Incidence of Uveitis Following Initiation of Prostaglandin Analogs Versus Other Glaucoma Medications: A Study from the SOURCE Repository.

Chauhan MZ, Elhusseiny AM, Marwah S, Sallam AB, Stein JD, Kishor KS, SOURCE Consortium , Amin S, Edwards PA, Srikumaran D, Woreta F, Schultz JS, Shrivastava A, Ahmad B, Pasquale L, Bryar PJ, French DD, Hribar M, Thomas M, Vanderbeek BL, Pershing S, Wang SY, Deiner M, Sun C, Patnaik J, Subramanian P, Munir S, Munir W, Stein JD, De Lott L, Ramachandran R, Feldman R, Stagg BC, Wirostko B, McMillian B, Sheybani A, Sarrapour S, Harris-Nwanyanwu K. Incidence of Uveitis Following Initiation of Prostaglandin Analogs Versus Other Glaucoma Medications: A Study from the SOURCE Repository. Ophthalmology. Glaucoma. 2024 Nov 12.

Dimensions for VA is a web-based tool available to VA staff that enables detailed searches of published research and research projects.

If you have VA-Intranet access, click here for more information vaww.hsrd.research.va.gov/dimensions/

VA staff not currently on the VA network can access Dimensions by registering for an account using their VA email address.    Search Dimensions for VA for this citation
* Don't have VA-internal network access or a VA email address? Try searching the free-to-the-public version of Dimensions

Search for Abstract from PubMed

---

Abstract:

PURPOSE: To evaluate the risk of incidence rates of uveitis among patients starting topical glaucoma therapy. DESIGN: Retrospective database study utilizing the Sight Outcomes Research Collaborative (SOURCE) Ophthalmology Data Repository. PARTICIPANTS: Adult glaucoma patients who were recently started on topical glaucoma therapy. METHODS: Using data from 10 health systems contributing data to the SOURCE data repository, we identified all adult glaucoma patients who had been newly started on a topical glaucoma medication (prostaglandin analogues (PGAs), beta-blockers (BBs), alpha agonists (AAs), and carbonic anhydrase inhibitors (CAIs)). Patients with pre-existing documentation of uveitis were excluded. MAIN OUTCOME MEASURES: Incidence of uveitis within 3 months of initiating therapy with different topical glaucoma medications. RESULTS: We included 67,517 patients who were newly prescribed a topical glaucoma medication. The mean age of the patients was 67.3±13.2 years and 59% were females. A total of 567 patients (0.87%) developed uveitis within 3 months of initiating the therapy. The incidence of uveitis was 0.32%, 1.95%, 1.63%, and 1.68% for users of PGAs, BBs, AAs, and CAIs, respectively. After adjusting for sociodemographic factors, individuals using topical BBs, AAs, and CAIs had significantly higher odds of developing uveitis versus those using PGAs (P < 0.001 for all comparisons). CONCLUSIONS: The use of PGAs was not associated with higher odds of developing uveitis compared to other classes of topical glaucoma medications.